| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632150 | CMP DEV LLC | Potassium phosphates composition for injection |
Apr, 2039
(15 years from now) | |
Potassium Phosphates is owned by Cmp Dev Llc.
Potassium Phosphates contains Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic.
Potassium Phosphates has a total of 1 drug patent out of which 0 drug patents have expired.
Potassium Phosphates was authorised for market use on 19 September, 2019.
Potassium Phosphates is available in solution;intravenous dosage forms.
Potassium Phosphates can be used as potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older.
The generics of Potassium Phosphates are possible to be released after 19 April, 2039.
Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient
Market Authorisation Date: 19 September, 2019
Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older
Dosage: SOLUTION;INTRAVENOUS
POTASSIUM PHOSPHATES family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic